Overview

• Sanofi will pay $600 million upfront and up to $1.3 billion in milestone payments to acquire Dren Bio’s DR-0201 therapy.
• DR-0201 is a CD20-directed bispecific antibody designed to deplete B-cells via targeted phagocytosis, currently in phase 1 clinical trials.
• Early studies suggest DR-0201 may reset the immune system and offer treatment-free remission for conditions like lupus.
• The acquisition aligns with Sanofi’s strategy to lead in immunology by leveraging innovative technologies for unmet medical needs.
• Dren Bio will remain independent post-acquisition to continue developing its pipeline of antibody-based therapeutics.